InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 -0.001 (-20%)+
Announcement
Release
24 Oct 2025 9:21AM
Price at Release
$0.005
Full Release
download
Summary
AdAlta Limited (ASX:1AD) announced the completion of its NLSC Investment Agreement, having repaid the remaining balance in cash, and thus no further shares will be issued under this agreement. The investment from New Life Sciences Capital (NLSC) provided essential liquidity and support for AdAlta during the initial stages of their 'East to West' cellular immunotherapy strategy. The company highlighted that the strategic flexibility offered by NLSC's investment was pivotal as AdAlta moves forward with advanced negotiations for its first CAR-T asset. This positioned the company to raise additional private capital to further their global initiative in providing cellular immunotherapies for solid cancers.
Key Points
  • AdAlta repaid the remaining balance of NLSC investment in cash.
  • No further shares will be issued under the NLSC Investment Agreement.
  • NLSC's investment was crucial for AdAlta's 'East to West' strategy.
  • AdAlta is negotiating its first CAR-T asset development agreement.
  • The company aims to raise private capital for global cancer immunotherapy initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.